Natural Evolution of IgE Responses to Mite Allergens and Relationship to Progression of Allergic Disease: a Review

Current Allergy and Asthma Reports

Volumn 17, Issue 5, 2017, Pages

  Posa, Daniela ^a   Hofmaier, Stephanie ^a   Arasi, Stefania ^a   Matricardi, Paolo Maria ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Allergic rhinitis; Asthma; House dust mite; IgE response; Molecular allergology; Specific immunotherapy

Indexed keywords

DER P 1 ALLERGEN; DER P 10 ALLERGEN; DER P 2 ALLERGEN; DER P 23 ALLERGEN; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; UNCLASSIFIED DRUG; ALLERGEN;

ALLERGIC RHINITIS; ASTHMA; BLOMIA TROPICALIS; CROSS-SECTIONAL STUDY; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE COURSE; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOREACTIVITY; IMMUNOTHERAPY; IN VITRO STUDY; LONGITUDINAL STUDY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROVOCATION TEST; RESPIRATORY TRACT ALLERGY; REVIEW; RISK FACTOR; SENSITIZATION; SKIN TEST; ANIMAL; IMMUNOLOGY; PROCEDURES; PYROGLYPHIDAE;

ALLERGENS; ANIMALS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN E; IMMUNOTHERAPY; PYROGLYPHIDAE; RISK FACTORS;

EID: 85018525840     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-017-0697-y     Document Type: Review

References (71)

1. Tovey ER, Chapman MD, Wells CW, Platts-Mills TA. The distribution of dust mite allergen in the houses of patients with asthma. Am Rev Respir Dis. 1981;124(5):630–5. doi:10.1164/arrd.1981.124.5.630.
2. Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P, Jarvis D, et al. Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I. Allergy. 2007;62(3):301–9. doi:10.1111/j.1398-9995.2006.01293.x.
3. Blomme K, Tomassen P, Lapeere H, Huvenne W, Bonny M, Acke F, et al. Prevalence of allergic sensitization versus allergic rhinitis symptoms in an unselected population. Int Arch Allergy Immunol. 2013;160(2):200–7. doi:10.1159/000339853.
4. Johnston JD, Barney T, Crandall J, Brown M, Westover T, Paulson S, et al. Prevalence of house dust mite allergens in low-income homes with evaporative coolers in a semi-arid climate. Archives of environmental & occupational health. 2017; doi:10.1080/19338244.2017.1282846.
5. • Calderon MA, Linneberg A, Kleine-Tebbe J, De Blay F, De Hernandez Fernandez Rojas D, Virchow JC, et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol. 2015;136(1):38–48. doi:10.1016/j.jaci.2014.10.012. Extensive review on the relationship between exposure to house dust mite, allergic response and development of allergic airways diseases
6. • Linneberg A, Dam Petersen K, Hahn-Pedersen J, Hammerby E, Serup-Hansen N, Boxall N. Burden of allergic respiratory disease: a systematic review. Clinical and molecular allergy: CMA. 2016;14:12. doi:10.1186/s12948-016-0049-9. This meta-analysis demonstrates the low level of the health-related quality of life (HRQL) of patients with perennial HDM allergy in comparison with patients with seasonal pollen allergy
7. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–43. doi:10.1016/S0140-6736(06)69283-0.
8. Ellwood P, Asher MI, Billo NE, Bissell K, Chiang CY, Ellwood EM, et al. The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors. Eur Respir J. 2017;49(1) doi:10.1183/13993003.01605-2016.
9. Gandhi VD, Davidson C, Asaduzzaman M, Nahirney D, Vliagoftis H. House dust mite interactions with airway epithelium: role in allergic airway inflammation. Curr Allergy Asthma Rep. 2013;13(3):262–70. doi:10.1007/s11882-013-0349-9.
10. Marks GB, Mihrshahi S, Kemp AS, Tovey ER, Webb K, Almqvist C, et al. Prevention of asthma during the first 5 years of life: a randomized controlled trial. J Allergy Clin Immunol. 2006;118(1):53–61. doi:10.1016/j.jaci.2006.04.004.
11. Sporik R, Chapman MD, Platts-Mills TA. House dust mite exposure as a cause of asthma. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 1992;22(10):897–906.
12. Morgan WJ, Crain EF, Gruchalla RS, O'Connor GT, Kattan M, Evans 3rd R, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med. 2004;351(11):1068–80. doi:10.1056/NEJMoa032097.
13. van Schayck OC, Maas T, Kaper J, Knottnerus AJ, Sheikh A. Is there any role for allergen avoidance in the primary prevention of childhood asthma? J Allergy Clin Immunol. 2007;119(6):1323–8. doi:10.1016/j.jaci.2007.02.024.
14. Calderon MA, Kleine-Tebbe J, Linneberg A, De Blay F, Hernandez Fernandez de Rojas D, Virchow JC, et al. House dust mite respiratory allergy: an overview of current therapeutic strategies. The journal of allergy and clinical immunology In practice. 2015;3(6):843–55. doi:10.1016/j.jaip.2015.06.019.
15. Ciprandi G, Natoli V, Puccinelli P, Incorvaia C, Italian Cometa Study Group. Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world. Allergy, asthma, and clinical immunology: official journal of the Canadian Society of Allergy and Clin Immunol. 2017;13:11. doi:10.1186/s13223-017-0185-x.
16. Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Gronlund H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 1999;29(7):896–904.
17. Matricardi PM, Kleine-Tebbe J. Molecular allergology between Precision Medicine and the Choosing Wisely initiative. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2016;46(5):664–7. doi:10.1111/cea.12679.
18. Casset A, Mari A, Purohit A, Resch Y, Weghofer M, Ferrara R, et al. Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts. Int Arch Allergy Immunol. 2012;159(3):253–62. doi:10.1159/000337654.
19. Brunetto B, Tinghino R, Braschi MC, Antonicelli L, Pini C, Iacovacci P. Characterization and comparison of commercially available mite extracts for in vivo diagnosis. Allergy. 2010;65(2):184–90. doi:10.1111/j.1398-9995.2009.02150.x.
20. Sastre J. Molecular diagnosis in allergy. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2010;40(10):1442–60. doi:10.1111/j.1365-2222.2010.03585.x.
21. Treudler R, Simon JC. Overview of component resolved diagnostics. Curr Allergy Asthma Rep. 2013;13(1):110–7. doi:10.1007/s11882-012-0318-8.
22. Borres MP, Ebisawa M, Eigenmann PA. Use of allergen components begins a new era in pediatric allergology. Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology. 2011;22(5):454–61. doi:10.1111/j.1399-3038.2011.01197.x.
23. Canonica GW, Ansotegui IJ, Pawankar R, Schmid-Grendelmeier P, van Hage M, Baena-Cagnani CE, et al. A WAO - ARIA - GA(2)LEN consensus document on molecular-based allergy diagnostics. The World Allergy Organization journal. 2013;6(1):17. doi:10.1186/1939-4551-6-17.
24. •• Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, Hofmaier S, et al. EAACI molecular allergology user's guide. Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology. 2016;27(Suppl 23):1–250. doi:10.1111/pai.12563. Detailed summary of important allergens, description of diagnostic option through the use of component-resolved diagnostics and integration of molecular allergology into clinical practice
25. •• Hamilton RG, Kleine-Tebbe J. Molecular allergy diagnostics: analytical features that support clinical decisions. Curr Allergy Asthma Rep. 2015;15(9):57. doi:10.1007/s11882-015-0556-7. This paper provides documentation for the use of selected allergenic molecules to improve the clinician’s prediction of the risk of a serious allergic reaction
26. Sastre J, Landivar ME, Ruiz-Garcia M, Andregnette-Rosigno MV, Mahillo I. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy. 2012;67(5):709–11. doi:10.1111/j.1398-9995.2012.02808.x.
27. Stringari G, Tripodi S, Caffarelli C, Dondi A, Asero R, Di Rienzo BA, et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. J Allergy Clin Immunol. 2014;134(1):75–81. doi:10.1016/j.jaci.2014.01.042.
28. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol. 2002;2(6):446–53. doi:10.1038/nri824.
29. Chen KW, Blatt K, Thomas WR, Swoboda I, Valent P, Valenta R, et al. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J Allergy Clin Immunol. 2012;130(2):435–43. e4 doi:10.1016/j.jaci.2012.05.035.
30. Vrtala S, Huber H, Thomas WR. Recombinant house dust mite allergens. Methods. 2014;66(1):67–74. doi:10.1016/j.ymeth.2013.07.034.
31. Asturias JA, Ibarrola I, Arilla MC, Vidal C, Ferrer A, Gamboa PM, et al. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2009;39(7):1088–98. doi:10.1111/j.1365-2222.2009.03264.x.
32. •• Thomas WR. House dust mite allergens: new discoveries and relevance to the allergic patient. Curr Allergy Asthma Rep. 2016;16(9):69. doi:10.1007/s11882-016-0649-y. A comprehensive review on house dust allergens with important information about clinical and biological activity
33. Jeong KY, Lee JY, Son M, Yi MH, Yong TS, Shin JU, et al. Profiles of IgE sensitization to Der f 1, Der f 2, Der f 6, Der f 8, Der f 10, and Der f 20 in Korean house dust mite allergy patients. Allergy Asthma Immunol Res. 2015;7(5):483–8. doi:10.4168/aair.2015.7.5.483.
34. Caraballo L, Puerta L, Martinez B, Moreno L. Identification of allergens from the mite Blomia tropicalis. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 1994;24(11):1056–60.
35. Herman J, Thelen N, Smargiasso N, Mailleux AC, Luxen A, Cloes M, et al. Der p 1 is the primary activator of Der p 3, Der p 6 and Der p 9 the proteolytic allergens produced by the house dust mite Dermatophagoides pteronyssinus. Bba-Gen Subjects. 2014;1840(3):1117–24. doi:10.1016/j.bbagen2013.11.017.
36. Pacciani V, Corrente S, Gregori S, Pierantozzi A, Silenzi R, Chianca M, et al. Correlation of Der p 2 T-cell responses with clinical characteristics of children allergic to house dust mite. Ann Allergy Asthma Immunol. 2012;109(6):442–7. doi:10.1016/j.anai.2012.09.001.
37. Stewart GA, Kollinger MR, King CM, Thompson PJ. A comparative study of three serine proteases from Dermatophagoides pteronyssinus and Dermatophagoides farinae. Allergy. 1994;49(7):553–60.
38. Bronnert M, Mancini J, Birnbaum J, Agabriel C, Liabeuf V, Porri F, et al. Component-resolved diagnosis with commercially available D. pteronyssinus Der p 1, Der p 2 and Der p 10: relevant markers for house dust mite allergy. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2012;42(9):1406–15. doi:10.1111/j.1365-2222.2012.04035.x.
39. Vidal C, Lojo S, Juangorena M, Gonzalez-Quintela A. Association between asthma and sensitization to allergens of Dermatophagoides pteronyssinus. Journal of investigational allergology & clinical immunology. 2016;26(5):304–9. doi:10.18176/jiaci.0048.
40. Simpson A, Lazic N, Belgrave DC, Johnson P, Bishop C, Mills C, et al. Patterns of IgE responses to multiple allergen components and clinical symptoms at age 11 years. J Allergy Clin Immunol. 2015;136(5):1224–31. doi:10.1016/j.jaci.2015.03.027.
41. Reese G, Ayuso R, Lehrer SB. Tropomyosin: an invertebrate pan-allergen. Int Arch Allergy Immunol. 1999;119(4):247–58. doi: 24201
42. Resch Y, Weghofer M, Seiberler S, Horak F, Scheiblhofer S, Linhart B, et al. Molecular characterization of Der p 10: a diagnostic marker for broad sensitization in house dust mite allergy. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2011;41(10):1468–77. doi:10.1111/j.1365-2222.2011.03798.x.
43. • Custovic A, Sonntag HJ, Buchan IE, Belgrave D, Simpson A, Prosperi MC. Evolution pathways of IgE responses to grass and mite allergens throughout childhood. J Allergy Clin Immunol. 2015;136(6):1645–52 e1-8. doi:10.1016/j.jaci.2015.03.041. A longitudinal study on the development of the IgE response to grass and to mites in relation with clinical outcomes in the Manchester Asthma and Allergy Study (MAAS)
44. Dumez ME, Herman J, Campizi V, Galleni M, Jacquet A, Chevigne A. Orchestration of an uncommon maturation cascade of the house dust mite protease allergen quartet. Front Immunol. 2014;5:138. doi:10.3389/fimmu.2014.00138.
45. Weghofer M, Grote M, Resch Y, Casset A, Kneidinger M, Kopec J, et al. Identification of Der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J Immunol. 2013;190(7):3059–67. doi:10.4049/jimmunol.1202288.
46. •• Thomas WR. Hierarchy and molecular properties of house dust mite allergens. Allergology international: official journal of the Japanese Society of Allergology. 2015;64(4):304–11. doi:10.1016/j.alit.2015.05.004. Review on the spectrum of house dust mite allergic molecules with classification in serodominant, mid-tier and minor allergens
47. Mueller GA, Randall TA, Glesner J, Pedersen LC, Perera L, Edwards LL, et al. Serological, genomic and structural analyses of the major mite allergen Der p 23. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2016;46(2):365–76. doi:10.1111/cea.12680.
48. • Banerjee S, Resch Y, Chen KW, Swoboda I, Focke-Tejkl M, Blatt K, et al. Der p 11 is a major allergen for house dust mite-allergic patients suffering from atopic dermatitis. The Journal of investigative dermatology. 2015;135(1):102–9. doi:10.1038/jid.2014.271. The study reports a high prevalence of IgE reactivity to Der p 11, a paramyosin that occurs predominantly in muscle of Dermatophagoides pteronyssinus, in house dust mite allergic patients suffering from AD
49. Weghofer M, Grote M, Dall'Antonia Y, Fernandez-Caldas E, Krauth MT, van Hage M, et al. Characterization of folded recombinant Der p 5, a potential diagnostic marker allergen for house dust mite allergy. Int Arch Allergy Immunol. 2008;147(2):101–9. doi:10.1159/000135696.
50. O'Neil SE, Heinrich TK, Hales BJ, Hazell LA, Holt DC, Fischer K, et al. The chitinase allergens Der p 15 and Der p 18 from Dermatophagoides pteronyssinus. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2006;36(6):831–9. doi:10.1111/j.1365-2222.2006.02497.x.
51. Hales BJ, Elliot CE, Chai LY, Pearce LJ, Tipayanon T, Hazell L, et al. Quantitation of IgE binding to the chitinase and chitinase-like house dust mite allergens Der p 15 and Der p 18 compared to the major and mid-range allergens. Int Arch Allergy Immunol. 2013;160(3):233–40. doi:10.1159/000339760.
52. Weghofer M, Dall'Antonia Y, Grote M, Stocklinger A, Kneidinger M, Balic N, et al. Characterization of Der p 21, a new important allergen derived from the gut of house dust mites. Allergy. 2008;63(6):758–67. doi:10.1111/j.1398-9995.2008.01647.x.
53. Batard T, Baron-Bodo V, Martelet A, Le Mignon M, Lemoine P, Jain K, et al. Patterns of IgE sensitization in house dust mite-allergic patients: implications for allergen immunotherapy. Allergy. 2016;71(2):220–9. doi:10.1111/all.12796.
54. Weghofer M, Thomas WR, Kronqvist M, Mari A, Purohit A, Pauli G, et al. Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Investig. 2008;38(12):959–65. doi:10.1111/j.1365-2362.2008.02048.x.
55. •• Resch Y, Michel S, Kabesch M, Lupinek C, Valenta R, Vrtala S. Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children. J Allergy Clin Immunol. 2015;136(4):1083–91. doi:10.1016/j.jaci.2015.03.024. A cross-sectional study demonstrating that IgE response to Dermatophagoides pteronyssinus in asthmatic children is characterized by an expanded molecular repertoire and by an increased number of sIgE
56. Hatzler L, Panetta V, Lau S, Wagner P, Bergmann RL, Illi S, et al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol. 2012;130(4):894–901. e5 doi:10.1016/j.jaci.2012.05.053.
57. •• Posa D, Perna S, Resch Y, Lupinek C, Panetta V, Hofmaier S, et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life. J Allergy Clin Immunol. 2017;139(2):541–9 e8. doi:10.1016/j.jaci.2016.08.014. Birth cohort study that explores the IgE response to 12 molecules of Dermatophagoides pteronyssinus and its risk factors, and evaluate IgE patterns in relation to the evolution of clinical symptoms
58. Matricardi PM. Allergen-specific immunoprophylaxis: toward secondary prevention of allergic rhinitis? Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology. 2014;25(1):15–8. doi:10.1111/pai.12200.
59. Charpin D, Kleisbauer JP, Lanteaume A, Razzouk H, Vervloet D, Toumi M, et al. Asthma and allergy to house-dust mites in populations living in high altitudes. Chest. 1988;93(4):758–61.
60. Platts-Mills TA, Tovey ER, Mitchell EB, Moszoro H, Nock P, Wilkins SR. Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet. 1982;2(8300):675–8.
61. Boner AL, Niero E, Antolini I, Valletta EA, Gaburro D. Pulmonary function and bronchial hyperreactivity in asthmatic children with house dust mite allergy during prolonged stay in the Italian Alps (Misurina, 1756 m). Annals of allergy. 1985;54(1):42–5.
62. Tsurikisawa N, Saito A, Oshikata C, Yasueda H, Akiyama K. Effective allergen avoidance for reducing exposure to house dust mite allergens and improving disease management in adult atopic asthmatics. The Journal of asthma: official journal of the Association for the Care of Asthma. 2016;53(8):843–53. doi:10.3109/02770903.2016.1155218.
63. Illi S, von Mutius E, Lau S, Niggemann B, Gruber C, Wahn U, et al. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet. 2006;368(9537):763–70. doi:10.1016/S0140-6736(06)69286-6.
64. Bachert C, Larche M, Bonini S, Canonica GW, Kundig T, Larenas-Linnemann D, et al. Allergen immunotherapy on the way to product-based evaluation—a WAO statement. The World Allergy Organization journal. 2015;8(1):29. doi:10.1186/s40413-015-0078-8.
65. •• Kristiansen M, Dhami S, Netuveli G, Halken S, Muraro A, Roberts G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology. 2017;28(1):18–29. doi:10.1111/pai.12661. Detailed review on the role of Immunotherapy in the prevention of Allergy: evaluation of 32 studies about SCIT, oral and SLIT including children and/or adults
66. Pifferi M, Baldini G, Marrazzini G, Baldini M, Ragazzo V, Pietrobelli A, et al. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy. 2002;57(9):785–90.
67. Szepfalusi Z, Bannert C, Ronceray L, Mayer E, Hassler M, Wissmann E, et al. Preventive sublingual immunotherapy in preschool children: first evidence for safety and pro-tolerogenic effects. Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology. 2014;25(8):788–95. doi:10.1111/pai.12310.
68. • Zolkipli Z, Roberts G, Cornelius V, Clayton B, Pearson S, Michaelis L, et al. Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood. J Allergy Clin Immunol. 2015;136(6):1541–7 e1-11. doi:10.1016/j.jaci.2015.04.045. This is the first primary prevention study of allergen immunotherapy in infancy evaluating a potential protective effect of high-dose HDM allergen extract on the development of atopy
69. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8. doi:10.1111/j.1398-9995.2007.01451.x.
70. Cromwell O, Matricardi PM, Fiebig H. Patient-tailored recombinant allergen products—mission impossible? Arbeiten aus dem Paul-Ehrlich-Institut. 2009;96:210–7. discussion 7-8
71. • Berings M, Arasi S, De Ruyck N, Perna S, Resch Y, Lupinek C, et al. Reliable mite-specific IgE testing in nasal secretions by means of allergen microarray. J Allergy Clin Immunol. 2017; doi:10.1016/j.jaci.2016.11.047. The first study performed with a customized microarray for IgE to allergen components of House Dust Mite in nasal secretions of patients suffering from HDM allergic rhinitis